Telehealth firm Hims & Hers reports a Q2 per-share loss of $0.37, down from a $0.17 profit a year earlier, due to one-time costs.
Hims & Hers Health (HIMS) shares trimmed earlier losses after reporting a second-quarter loss of $0.37 per share, reversing a $0.17 profit from the same period last year. The decline was driven by an $81 million one-time charge, including acquisition and restructuring costs tied to its weight-loss strategy shift and legal reserves related to FTC litigation.
Gross margins fell to 64% from 76% in the prior-year quarter. The company has been navigating regulatory challenges and a pivot away from compounded GLP-1 drugs, focusing instead on partnerships with pharmaceutical manufacturers. Recent FTC allegations over data-sharing and subscription practices have added pressure.
Shares initially dropped 3% before paring losses, reflecting investor reaction to the wider-than-expected loss and ongoing legal risks.